IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
IncobotulinumtoxinA (Xeomin) is a botulinum toxin type A preparation free of complexing
proteins, i.e. free of proteins other than the active toxin. Injected into the muscle,
IncobotulinumtoxinA (Xeomin) causes local weakening. Botulinum toxin type A is widely used
for aesthetic treatment of facial lines. This study investigated the efficacy and safety of
IncobotulinumtoxinA (Xeomin) in the treatment of glabellar frown lines compared to placebo.
The study consisted of a Main Period and an Open-Label Extension [OLEX] Period of 120 days
each.
Phase:
Phase 3
Details
Lead Sponsor:
Merz Pharmaceuticals GmbH
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA